Print Page     Close Window     

Investor Home

Corporate Profile

BeiGene, Ltd. (“BeiGene”) is a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer.

BeiGene has a broad portfolio consisting of six internally-developed, clinical-stage, drug candidates, including three late-stage clinical drug candidates, zanubrutinib (BTK inhibitor), tisle...more >

Stock Quotemore >
BGNE (American Depositary Shares)

$127.02

 0.02 (0.02%)

11/16/18  4:00 p.m. ET

Currency is USD
Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent Press Releasesmore >
BeiGene Announces Preliminary Clinical Data on PARP Inhibitor Pamiparib Presented at Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology - November 16, 2018
CAMBRIDGE, Mass., and BEIJING, China, Nov. 16, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a c... Read More
Priority Review Granted to BeiGene’s New Drug Applications for Zanubrutinib and Tislelizumab in China - November 15, 2018
CAMBRIDGE, Mass., and BEIJING, China, Nov. 15, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a c... Read More

Upcoming Events

There are currently no events scheduled.

E-mail Alerts

Sign up to receive e-mail alerts
 

© 2016 BeiGene. All Rights Reserved.